Fortrea sells enabling services and patient access businesses for up to $345 mln

Adds details throughout

March 11 (Reuters) - Contract research firm Fortrea Holdings FTRE.O on Monday said it will sell two of its businesses to private equity firm Arsenal Capital Partners for up to $345 million.

The North Carolina-based company said it will receive $295 million for its enabling services segment and patient access businesses when the deal closes in the second quarter of 2024, with a further $50 million to be paid upon reaching specific transition-related milestones.

"After undertaking a strategic review of our business, divesting Endpoint and Fortrea Patient Access aligns with the interests of our customers," Fortrea Chairman and CEO Tom Pike said in a statement.

The endpoint clinical segment provides solutions to biopharmaceutical and contract research customers in serving complex and late-stage clinical trials.

Fortrea's patient access business provides patient support, product access, affordability and adherence solutions.

The company said the proposed divestiture further streamlines Fortrea's strategic focus as a pure-play contract research organization.

(Reporting by Pratik Jain in Bengaluru; Editing by Anil D'Silva and Tasim Zahid)


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.